There was little question the US FDA would approve Aegerion Pharmaceuticals' Juxtapid (lomitapide), a microsomal triglyceride transfer protein inhibitor intended to treat patients with homozygous familial hyperchodlesterolemia (HoFH) – with that OK coming about a week ahead of its 29 December Prescription Drug User Fee Act action date.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?